For several years, Loeb & Loeb tried to maneuver the delicate politics involved in representing both brand-name and generic drug companies.

But amid business pressures and conflicts that have forced other firms to take a side on intellectual property matters, Loeb & Loeb earlier this year did just that, choosing to represent only brand names going forward.